{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:00:04Z","timestamp":1790683204315,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s10072-020-04243-6","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T05:48:26Z","timestamp":1578894506000},"page":"1391-1404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["The efficacy of statins in the treatment of Alzheimer\u2019s disease: a meta-analysis of randomized controlled trial"],"prefix":"10.1007","volume":"41","author":[{"given":"Kun","family":"Xuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbo","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8651-8059","authenticated-orcid":false,"given":"Yehuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"issue":"8","key":"4243_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.arcmed.2012.11.003","volume":"43","author":"AL Sosa-Ortiz","year":"2012","unstructured":"Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ (2012) Epidemiology of dementias and Alzheimer\u2019s disease. Arch Med Res 43(8):600\u2013608. https:\/\/doi.org\/10.1016\/j.arcmed.2012.11.003","journal-title":"Arch Med Res"},{"issue":"4","key":"4243_CR2","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1037\/a0029857","volume":"27","author":"RS Wilson","year":"2012","unstructured":"Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizel LP, Bennett DA (2012) The natural history of cognitive decline in Alzheimer\u2019s disease. Psychol Aging 27(4):1008\u20131017. https:\/\/doi.org\/10.1037\/a0029857","journal-title":"Psychol Aging"},{"key":"4243_CR3","volume-title":"World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future","author":"M Prince","year":"2016","unstructured":"Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M (2016) World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future. Alzheimer\u2019s Disease International (ADI), London"},{"issue":"9882","key":"4243_CR4","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/s0140-6736(13)60221-4","volume":"381","author":"KY Chan","year":"2013","unstructured":"Chan KY, Wang W, Wu JJ, Liu L, Theodoratou E, Car J, Middleton L, Russ TC, Deary IJ, Campbell H, Wang W, Rudan I (2013) Epidemiology of Alzheimer\u2019s disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet 381(9882):2016\u20132023. https:\/\/doi.org\/10.1016\/s0140-6736(13)60221-4","journal-title":"Lancet"},{"issue":"1","key":"4243_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2013.01.012","volume":"10","author":"J Jia","year":"2014","unstructured":"Jia J, Wang F, Wei C, Zhou A, Jia X, Li F, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X (2014) The prevalence of dementia in urban and rural areas of China. Alzheimers Dement 10(1):1\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2013.01.012","journal-title":"Alzheimers Dement"},{"issue":"4","key":"4243_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jalz.2017.12.006","volume":"14","author":"J Jia","year":"2018","unstructured":"Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, Zhao L, Jin H, Xu H, Wang F, Zhou A, Zuo X, Wu L, Han Y, Han Y, Huang L, Wang Q, Li D, Chu C, Shi L, Gong M, Du Y, Zhang J, Zhang J, Zhou C, Lv J, Lv Y, Xie H, Ji Y, Li F, Yu E, Luo B, Wang Y, Yang S, Qu Q, Guo Q, Liang F, Zhang J, Tan L, Shen L, Zhang K, Zhang J, Peng D, Tang M, Lv P, Fang B, Chu L, Jia L, Gauthier S (2018) The cost of Alzheimer\u2019s disease in China and re-estimation of costs worldwide. Alzheimers Dement 14(4):483\u2013491. https:\/\/doi.org\/10.1016\/j.jalz.2017.12.006","journal-title":"Alzheimers Dement"},{"issue":"1","key":"4243_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cercor\/1.1.103","volume":"1","author":"SE Arnold","year":"1991","unstructured":"Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW (1991) The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer\u2019s disease. Cereb Cortex 1(1):103\u2013116. https:\/\/doi.org\/10.1093\/cercor\/1.1.103","journal-title":"Cereb Cortex"},{"issue":"1","key":"4243_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM (2018) Alzheimer\u2019s disease. Eur J Neurol 25(1):59\u201370. https:\/\/doi.org\/10.1111\/ene.13439","journal-title":"Eur J Neurol"},{"issue":"4","key":"4243_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/nrneurol.2014.44","volume":"10","author":"YJ Wang","year":"2014","unstructured":"Wang YJ (2014) Alzheimer disease: lessons from immunotherapy for Alzheimer disease. Nat Rev Neurol 10(4):188\u2013189. https:\/\/doi.org\/10.1038\/nrneurol.2014.44","journal-title":"Nat Rev Neurol"},{"issue":"9346","key":"4243_CR10","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346):1623\u20131630. https:\/\/doi.org\/10.1016\/S0140-6736(02)11600-X","journal-title":"Lancet"},{"issue":"13","key":"4243_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1212\/01.wnl.0000346461.00520.28","volume":"72","author":"MR Goldstein","year":"2009","unstructured":"Goldstein MR, Mascitelli L, Pezzetta F, Haan MN, Cramer C, Kalbfleisch J, Langa K, Galea S (2009) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 72(13):1190\u20131191. https:\/\/doi.org\/10.1212\/01.wnl.0000346461.00520.28","journal-title":"Neurology"},{"issue":"1\u20132","key":"4243_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.exger.2008.05.004","volume":"44","author":"van Vliet P, van de Water W, de Craen AJ, Westendorp RG","year":"2009","unstructured":"van Vliet P, van de Water W, de Craen AJ, Westendorp RG (2009) The influence of age on the association between cholesterol and cognitive function. Exp Gerontol 44(1\u20132):112\u2013122. https:\/\/doi.org\/10.1016\/j.exger.2008.05.004","journal-title":"Exp Gerontol"},{"key":"4243_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1741-7015-5-20","volume":"5","author":"B Wolozin","year":"2007","unstructured":"Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson\u2019s disease. BMC Med 5:20. https:\/\/doi.org\/10.1186\/1741-7015-5-20","journal-title":"BMC Med"},{"issue":"3","key":"4243_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/joim.12262","volume":"277","author":"CK Wu","year":"2015","unstructured":"Wu CK, Yang YH, Lin TT, Tsai CT, Hwang JJ, Lin JL, Chen PC, Chiang FT, Lin LY (2015) Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis. J Intern Med 277(3):343\u2013352. https:\/\/doi.org\/10.1111\/joim.12262","journal-title":"J Intern Med"},{"issue":"3","key":"4243_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3233\/jad-2010-091570","volume":"20","author":"B McGuinness","year":"2010","unstructured":"McGuinness B, Passmore P (2010) Can statins prevent or help treat Alzheimer\u2019s disease? J Alzheimers Dis 20(3):925\u2013933. https:\/\/doi.org\/10.3233\/jad-2010-091570","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"4243_CR16","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/archneur.62.7.1047","volume":"62","author":"TD Rea","year":"2005","unstructured":"Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH (2005) Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62(7):1047\u20131051. https:\/\/doi.org\/10.1001\/archneur.62.7.1047","journal-title":"Arch Neurol"},{"issue":"2","key":"4243_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/archpsyc.62.2.217","volume":"62","author":"PP Zandi","year":"2005","unstructured":"Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC (2005) Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62(2):217\u2013224. https:\/\/doi.org\/10.1001\/archpsyc.62.2.217","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"4243_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ejim.2015.08.012","volume":"26","author":"HL Daneschvar","year":"2015","unstructured":"Daneschvar HL, Aronson MD, Smetana GW (2015) Do statins prevent Alzheimer\u2019s disease? A narrative review. Eur J Intern Med 26(9):666\u2013669. https:\/\/doi.org\/10.1016\/j.ejim.2015.08.012","journal-title":"Eur J Intern Med"},{"issue":"6","key":"4243_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/CRD.0b013e3181f52a7f","volume":"18","author":"CG Mihos","year":"2010","unstructured":"Mihos CG, Salas MJ, Santana O (2010) The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev 18(6):298\u2013304. https:\/\/doi.org\/10.1097\/CRD.0b013e3181f52a7f","journal-title":"Cardiol Rev"},{"issue":"3","key":"4243_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/NEN.0b013e31819ac3cb","volume":"68","author":"M Boimel","year":"2009","unstructured":"Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, Rosenmann H (2009) Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol 68(3):314\u2013325. https:\/\/doi.org\/10.1097\/NEN.0b013e31819ac3cb","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"4243_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1179\/1743132812y.0000000054","volume":"34","author":"T Kurata","year":"2012","unstructured":"Kurata T, Miyazaki K, Kozuki M, Morimoto N, Ohta Y, Ikeda Y, Abe K (2012) Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer\u2019s disease. Neurol Res 34(6):601\u2013610. https:\/\/doi.org\/10.1179\/1743132812y.0000000054","journal-title":"Neurol Res"},{"issue":"1\u20132","key":"4243_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12031-002-0026-2","volume":"19","author":"SS Petanceska","year":"2002","unstructured":"Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T, Duff K, Pappolla M, Refolo LM (2002) Statin therapy for Alzheimer\u2019s disease: will it work? J Mol Neurosci 19(1\u20132):155\u2013161. https:\/\/doi.org\/10.1007\/s12031-002-0026-2","journal-title":"J Mol Neurosci"},{"issue":"3","key":"4243_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11011-016-9803-4","volume":"31","author":"D Zhou","year":"2016","unstructured":"Zhou D, Liu H, Li C, Wang F, Shi Y, Liu L, Zhao X, Liu A, Zhang J, Wang C, Chen Z (2016) Atorvastatin ameliorates cognitive impairment, Abeta1-42 production and Tau hyperphosphorylation in APP\/PS1 transgenic mice. Metab Brain Dis 31(3):693\u2013703. https:\/\/doi.org\/10.1007\/s11011-016-9803-4","journal-title":"Metab Brain Dis"},{"issue":"19 Pt 2","key":"4243_CR24","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1212\/01.wnl.0000288181.00826.63","volume":"70","author":"Z Arvanitakis","year":"2008","unstructured":"Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, Bennett DA (2008) Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70(19 Pt 2):1795\u20131802. https:\/\/doi.org\/10.1212\/01.wnl.0000288181.00826.63","journal-title":"Neurology"},{"issue":"12","key":"4243_CR25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","volume":"74","author":"HH Feldman","year":"2010","unstructured":"Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74(12):956\u2013964. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d6476a","journal-title":"Neurology"},{"issue":"12","key":"4243_CR26","doi-asserted-by":"publisher","first-page":"e115755","DOI":"10.1371\/journal.pone.0115755","volume":"9","author":"H Joosten","year":"2014","unstructured":"Joosten H, Visser ST, van Eersel ME, Gansevoort RT, Bilo HJ, Slaets JP, Izaks GJ (2014) Statin use and cognitive function: population-based observational study with long-term follow-up. PLoS One 9(12):e115755. https:\/\/doi.org\/10.1371\/journal.pone.0115755","journal-title":"PLoS One"},{"issue":"6","key":"4243_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","volume":"77","author":"M Sano","year":"2011","unstructured":"Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS (2011) A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77(6):556\u2013563. https:\/\/doi.org\/10.1212\/WNL.0b013e318228bf11","journal-title":"Neurology"},{"issue":"1","key":"4243_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13195-017-0237-y","volume":"9","author":"N Geifman","year":"2017","unstructured":"Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ (2017) Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer\u2019s disease. Alzheimers Res Ther 9(1):10. https:\/\/doi.org\/10.1186\/s13195-017-0237-y","journal-title":"Alzheimers Res Ther"},{"issue":"1\u20133","key":"4243_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000295660","volume":"7","author":"DL Sparks","year":"2010","unstructured":"Sparks DL, Kryscio RJ, Connor DJ, Sabbagh MN, Sparks LM, Lin Y, Liebsack C (2010) Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegener Dis 7(1\u20133):183\u2013186. https:\/\/doi.org\/10.1159\/000295660","journal-title":"Neurodegener Dis"},{"key":"4243_CR30","unstructured":"Pandey R, Jha D, Pandey P, Gupta P, Shah V (2017) An indirect treatment comparison of unapproved treatment options of Alzheimer's disease for research prioritization. Value Health 20(5): A311-A312."},{"issue":"7","key":"4243_CR31","doi-asserted-by":"publisher","first-page":"A810","DOI":"10.1016\/j.jval.2016.08.708","volume":"19","author":"R Pandey","year":"2016","unstructured":"Pandey R, Jha D, Pandey P, Shah V (2016) Network meta-analysis of randomized trials to compare the efficacy of Nsaids, statins and vitamins in Alzheimer\u2019s disease. Value Health 19(7):A810. https:\/\/doi.org\/10.1016\/j.jval.2016.08.708","journal-title":"Value Health"},{"issue":"7","key":"4243_CR32","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100","journal-title":"PLoS Med"},{"issue":"11","key":"4243_CR33","doi-asserted-by":"publisher","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","volume":"135","author":"LL Kjaergard","year":"2001","unstructured":"Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135(11):982\u2013989. https:\/\/doi.org\/10.7326\/0003-4819-135-11-200112040-00010","journal-title":"Ann Intern Med"},{"issue":"7414","key":"4243_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"issue":"3","key":"4243_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/1567205054367900","volume":"2","author":"DL Sparks","year":"2005","unstructured":"Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolkowski C (2005) Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr Alzheimer Res 2(3):343\u2013353. https:\/\/doi.org\/10.2174\/1567205054367900","journal-title":"Curr Alzheimer Res"},{"key":"4243_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biopha.2017.05.060","volume":"92","author":"W Huang","year":"2017","unstructured":"Huang W, Li Z, Zhao L, Zhao W (2017) Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer\u2019s disease via modulating the expression of miR-106b. Biomed Pharmacother 92:46\u201357. https:\/\/doi.org\/10.1016\/j.biopha.2017.05.060","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"4243_CR37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/ana.10292","volume":"52","author":"M Simons","year":"2002","unstructured":"Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer\u2019s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52(3):346\u2013350. https:\/\/doi.org\/10.1002\/ana.10292","journal-title":"Ann Neurol"},{"key":"4243_CR38","first-page":"9","volume":"21","author":"XL Zhao","year":"2010","unstructured":"Zhao XL, Liu Y, Zhang Z, Zeng Z, Gao L, Yang X, Deng X, Zhu X (2010) Effect and safety of atrovastatin combined with memantine with moderate to severe Alzheimer\u2019s disease. Chin J Pract Nerv Dis 21:9\u201311","journal-title":"Chin J Pract Nerv Dis"},{"key":"4243_CR39","first-page":"52","volume":"3","author":"XL Zhao","year":"2011","unstructured":"Zhao XL, Liu Y (2011) Effect of Donepezil and Atrovastatin on moderate or severe Alzheimer disease and its safety. Pract J Clin Med 3:52\u201354","journal-title":"Pract J Clin Med"},{"key":"4243_CR40","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.6039\/j.issn.1001-0408.2013.20.11","volume":"20","author":"J Wu","year":"2013","unstructured":"Wu J, Fu Z, Chen Y (2013) Clinical observation of atorvastatin calcium combined with Donepezil hydrochloride in the treatment of Alzheimer disease. China Pharm 20:1855\u20131857. https:\/\/doi.org\/10.6039\/j.issn.1001-0408.2013.20.11","journal-title":"China Pharm"},{"key":"4243_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3969\/j.issn.1008-5971.2016.09.042","volume":"9","author":"SJ Wang","year":"2016","unstructured":"Wang SJ, Wang N, Jin JH (2016) Clinical effect of simvastatin on mild to moderate senile demetia patients with hyperlipaemia. Pract J Card Cereb Pneumal Vasc Dis 9:141\u2013142. https:\/\/doi.org\/10.3969\/j.issn.1008-5971.2016.09.042","journal-title":"Pract J Card Cereb Pneumal Vasc Dis"},{"issue":"8","key":"4243_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3109\/00207454.2013.778846","volume":"123","author":"RD Pandey","year":"2013","unstructured":"Pandey RD, Gupta PP, Jha D, Kumar S (2013) Role of statins in Alzheimer\u2019s disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs. Int J Neurosci 123(8):521\u2013525. https:\/\/doi.org\/10.3109\/00207454.2013.778846","journal-title":"Int J Neurosci"},{"issue":"5\u20136","key":"4243_CR43","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000382128","volume":"73","author":"T Liang","year":"2015","unstructured":"Liang T, Li R, Cheng O (2015) Statins for treating Alzheimer\u2019s disease: truly ineffective? Eur Neurol 73(5\u20136):360\u2013366. https:\/\/doi.org\/10.1159\/000382128","journal-title":"Eur Neurol"},{"issue":"22","key":"4243_CR44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.21037\/atm.2018.06.43","volume":"6","author":"X-C Zhu","year":"2018","unstructured":"Zhu X-C, Dai W-Z, Ma T (2018) Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis. Ann Transl Med 6(22):435\u2013435. https:\/\/doi.org\/10.21037\/atm.2018.06.43","journal-title":"Ann Transl Med"},{"issue":"4","key":"4243_CR45","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jpsychires.2008.04.014","volume":"43","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell AJ (2009) A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res 43(4):411\u2013431. https:\/\/doi.org\/10.1016\/j.jpsychires.2008.04.014","journal-title":"J Psychiatr Res"},{"issue":"6","key":"4243_CR46","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2169\/internalmedicine.56.7703","volume":"56","author":"K Toyama","year":"2017","unstructured":"Toyama K, Sugiyama S, Oka H, Hamada M, Iwasaki Y, Horio E, Rokutanda T, Nakamura S, Spin JM, Tsao PS, Ogawa H (2017) A pilot study: the beneficial effects of combined statin-exercise therapy on cognitive function in patients with coronary artery disease and mild cognitive decline. Intern Med 56(6):641\u2013649. https:\/\/doi.org\/10.2169\/internalmedicine.56.7703","journal-title":"Intern Med"},{"issue":"47","key":"4243_CR47","doi-asserted-by":"publisher","first-page":"e2143","DOI":"10.1097\/md.0000000000002143","volume":"94","author":"FC Lin","year":"2015","unstructured":"Lin FC, Chuang YS, Hsieh HM, Lee TC, Chiu KF, Liu CK, Wu MT (2015) Early statin use and the progression of Alzheimer disease: a total population-based case-control study. Medicine 94(47):e2143. https:\/\/doi.org\/10.1097\/md.0000000000002143","journal-title":"Medicine"},{"issue":"5 Suppl 6","key":"4243_CR48","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","volume":"48","author":"JL Cummings","year":"1997","unstructured":"Cummings JL (1997) The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48(5 Suppl 6):S10\u2013S16","journal-title":"Neurology"},{"issue":"6","key":"4243_CR49","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/arclin\/acw049","volume":"31","author":"ME Mlinac","year":"2016","unstructured":"Mlinac ME, Feng MC (2016) Assessment of activities of daily living, self-care, and independence. Arch Clin Neuropsychol 31(6):506\u2013516. https:\/\/doi.org\/10.1093\/arclin\/acw049","journal-title":"Arch Clin Neuropsychol"},{"issue":"3","key":"4243_CR50","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jacl.2018.02.012","volume":"12","author":"MJ Korhonen","year":"2018","unstructured":"Korhonen MJ, Ilomaki J, Sluggett JK, Brookhart MA, Visvanathan R, Cooper T, Robson L, Bell JS (2018) Selective prescribing of statins and the risk of mortality, hospitalizations, and falls in aged care services. J Clin Lipidol 12(3):652\u2013661. https:\/\/doi.org\/10.1016\/j.jacl.2018.02.012","journal-title":"J Clin Lipidol"},{"issue":"1","key":"4243_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ncl.2015.08.001","volume":"34","author":"GR Finney","year":"2016","unstructured":"Finney GR, Minagar A, Heilman KM (2016) Assessment of mental status. Neurol Clin 34(1):1\u201316. https:\/\/doi.org\/10.1016\/j.ncl.2015.08.001","journal-title":"Neurol Clin"},{"issue":"2","key":"4243_CR52","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3233\/JAD-2008-13209","volume":"13","author":"CM Carlsson","year":"2008","unstructured":"Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, Schreiber NT, Johnson SC, Atwood CS, Puglielli L, Hermann BP, McBride PE, Stein JH, Sager MA, Asthana S (2008) Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer\u2019s disease. J Alzheimers Dis 13(2):187\u2013197","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"4243_CR53","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/s1474-4422(17)30113-8","volume":"16","author":"D Chan","year":"2017","unstructured":"Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, Wilkie D, Nicholas R, Chataway J (2017) Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol 16(8):591\u2013600. https:\/\/doi.org\/10.1016\/s1474-4422(17)30113-8","journal-title":"Lancet Neurol"},{"issue":"5","key":"4243_CR54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/JGP.0b013e31816b72d4","volume":"16","author":"KJ Anstey","year":"2008","unstructured":"Anstey KJ, Lipnicki DM, Low LF (2008) Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 16(5):343\u2013354. https:\/\/doi.org\/10.1097\/JGP.0b013e31816b72d4","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"4243_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WAD.0b013e318187541c","volume":"23","author":"C Purnell","year":"2009","unstructured":"Purnell C, Gao S, Callahan CM, Hendrie HC (2009) Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord 23(1):1\u201310. https:\/\/doi.org\/10.1097\/WAD.0b013e318187541c","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"12","key":"4243_CR56","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/iub.1091","volume":"64","author":"R Ricciarelli","year":"2012","unstructured":"Ricciarelli R, Canepa E, Marengo B, Marinari UM, Poli G, Pronzato MA, Domenicotti C (2012) Cholesterol and Alzheimer\u2019s disease: a still poorly understood correlation. IUBMB Life 64(12):931\u2013935. https:\/\/doi.org\/10.1002\/iub.1091","journal-title":"IUBMB Life"},{"issue":"3","key":"4243_CR57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1582-4934.2007.00054.x","volume":"11","author":"PC Reid","year":"2007","unstructured":"Reid PC, Urano Y, Kodama T, Hamakubo T (2007) Alzheimer\u2019s disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 11(3):383\u2013392. https:\/\/doi.org\/10.1111\/j.1582-4934.2007.00054.x","journal-title":"J Cell Mol Med"},{"issue":"1\u20132","key":"4243_CR58","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jns.2009.02.352","volume":"283","author":"N Kandiah","year":"2009","unstructured":"Kandiah N, Feldman HH (2009) Therapeutic potential of statins in Alzheimer\u2019s disease. J Neurol Sci 283(1\u20132):230\u2013234. https:\/\/doi.org\/10.1016\/j.jns.2009.02.352","journal-title":"J Neurol Sci"},{"key":"4243_CR59","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1600-0404.2006.00685.x","volume":"185","author":"M Kivipelto","year":"2006","unstructured":"Kivipelto M, Solomon A (2006) Cholesterol as a risk factor for Alzheimer\u2019s disease - epidemiological evidence. Acta Neurol Scand Suppl 185:50\u201357. https:\/\/doi.org\/10.1111\/j.1600-0404.2006.00685.x","journal-title":"Acta Neurol Scand Suppl"},{"issue":"4","key":"4243_CR60","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1159\/000164271","volume":"26","author":"L Li","year":"2008","unstructured":"Li L, Cao D, Desmond R, Rahman A, Lah JJ, Levey AI, Zamrini E (2008) Cognitive performance and plasma levels of homocysteine, vitamin B12, folate and lipids in patients with Alzheimer disease. Dement Geriatr Cogn Disord 26(4):384\u2013390. https:\/\/doi.org\/10.1159\/000164271","journal-title":"Dement Geriatr Cogn Disord"},{"key":"4243_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-0404.2006.00690.x","volume":"185","author":"DL Sparks","year":"2006","unstructured":"Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P (2006) Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer\u2019s Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 185:3\u20137. https:\/\/doi.org\/10.1111\/j.1600-0404.2006.00690.x","journal-title":"Acta Neurol Scand Suppl"},{"issue":"5123","key":"4243_CR62","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science (New York, NY) 261(5123):921\u2013923. https:\/\/doi.org\/10.1126\/science.8346443","journal-title":"Science (New York, NY)"},{"issue":"8","key":"4243_CR63","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1194\/jlr.R075408","volume":"58","author":"GW Rebeck","year":"2017","unstructured":"Rebeck GW (2017) The role of APOE on lipid homeostasis and inflammation in normal brains. J Lipid Res 58(8):1493\u20131499. https:\/\/doi.org\/10.1194\/jlr.R075408","journal-title":"J Lipid Res"},{"key":"4243_CR64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1742-2094-11-111","volume":"11","author":"GA Rodriguez","year":"2014","unstructured":"Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW (2014) Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition. J Neuroinflammation 11:111. https:\/\/doi.org\/10.1186\/1742-2094-11-111","journal-title":"J Neuroinflammation"},{"key":"4243_CR65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neulet.2017.03.003","volume":"646","author":"FF de Oliveira","year":"2017","unstructured":"de Oliveira FF, Chen ES, Smith MC, Bertolucci PHF (2017) Longitudinal lipid profile variations and clinical change in Alzheimer\u2019s disease dementia. Neurosci Lett 646:36\u201342. https:\/\/doi.org\/10.1016\/j.neulet.2017.03.003","journal-title":"Neurosci Lett"},{"issue":"2","key":"4243_CR66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/153331750502000208","volume":"20","author":"AB Reiss","year":"2005","unstructured":"Reiss AB (2005) Cholesterol and apolipoprotein E in Alzheimer\u2019s disease. Am J Alzheimers Dis Other Dement 20(2):91\u201396. https:\/\/doi.org\/10.1177\/153331750502000208","journal-title":"Am J Alzheimers Dis Other Dement"},{"issue":"8","key":"4243_CR67","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/s1474-4422(14)70136-x","volume":"13","author":"S Norton","year":"2014","unstructured":"Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention of Alzheimer\u2019s disease: an analysis of population-based data. Lancet Neurol 13(8):788\u2013794. https:\/\/doi.org\/10.1016\/s1474-4422(14)70136-x","journal-title":"Lancet Neurol"},{"issue":"2","key":"4243_CR68","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/1871527314666150217123147","volume":"14","author":"A Safouris","year":"2015","unstructured":"Safouris A, Psaltopoulou T, Sergentanis TN, Boutati E, Kapaki E, Tsivgoulis G (2015) Vascular risk factors and Alzheimer\u2019s disease pathogenesis: are conventional pharmacological approaches protective for cognitive decline progression? CNS Neurol Disord Drug Targets 14(2):257\u2013269. https:\/\/doi.org\/10.2174\/1871527314666150217123147","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"10","key":"4243_CR69","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2012.07.007","volume":"60","author":"JW Jukema","year":"2012","unstructured":"Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S (2012) The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 60(10):875\u2013881. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.007","journal-title":"J Am Coll Cardiol"},{"key":"4243_CR70","unstructured":"Food and Drug Administration, Services UDoHaH (2012) FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm293101.htm#hcp Published February 28, 2012 28"},{"key":"4243_CR71","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40035-018-0110-3","volume":"7","author":"BG Schultz","year":"2018","unstructured":"Schultz BG, Patten DK, Berlau DJ (2018) The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener 7:5. https:\/\/doi.org\/10.1186\/s40035-018-0110-3","journal-title":"Transl Neurodegener"},{"issue":"3","key":"4243_CR72","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","volume":"30","author":"BR Ott","year":"2015","unstructured":"Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, Trikalinos TA (2015) Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med 30(3):348\u2013358. https:\/\/doi.org\/10.1007\/s11606-014-3115-3","journal-title":"J Gen Intern Med"},{"issue":"6","key":"4243_CR73","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.tcm.2016.03.009","volume":"26","author":"K Samaras","year":"2016","unstructured":"Samaras K, Brodaty H, Sachdev PS (2016) Does statin use cause memory decline in the elderly? Trends Cardiovasc Med 26(6):550\u2013565. https:\/\/doi.org\/10.1016\/j.tcm.2016.03.009","journal-title":"Trends Cardiovasc Med"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04243-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-020-04243-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04243-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T21:43:47Z","timestamp":1610487827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-020-04243-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["4243"],"URL":"https:\/\/doi.org\/10.1007\/s10072-020-04243-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"20 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"This work does not involve informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}